Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation / 전남의대학술지
Chonnam Medical Journal
;
: 6-11, 2020.
Artigo
em Inglês
| WPRIM
| ID: wpr-787280
ABSTRACT
Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Nações Unidas
/
Receptores de Antígenos
/
Linfócitos T
/
Causas de Morte
/
Terapia Combinada
/
Carcinogênese
/
Terapia Baseada em Transplante de Células e Tecidos
/
Sistema Imunitário
/
Ligantes
/
Reações Antígeno-Anticorpo
Limite:
Humanos
Idioma:
Inglês
Revista:
Chonnam Medical Journal
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS